Invention Grant
US08389472B2 Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
有权
毒蜥外泌肽治疗非酒精性脂肪性肝炎和非酒精性脂肪性肝病
- Patent Title: Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
- Patent Title (中): 毒蜥外泌肽治疗非酒精性脂肪性肝炎和非酒精性脂肪性肝病
-
Application No.: US12063712Application Date: 2006-08-21
-
Publication No.: US08389472B2Publication Date: 2013-03-05
- Inventor: Alain D. Baron , Dennis Kim , David G. Maggs , Matthew Wintle
- Applicant: Alain D. Baron , Dennis Kim , David G. Maggs , Matthew Wintle
- Applicant Address: US CA San Diego US DE Wilmington
- Assignee: Amylin Pharmaceuticals, LLC,AstraZeneca Pharmaceuticals LP
- Current Assignee: Amylin Pharmaceuticals, LLC,AstraZeneca Pharmaceuticals LP
- Current Assignee Address: US CA San Diego US DE Wilmington
- Agency: Womble Carlyle Sandridge & Rice LLP
- International Application: PCT/US2006/032661 WO 20060821
- International Announcement: WO2007/022518 WO 20070222
- Main IPC: A61K38/26
- IPC: A61K38/26 ; A61K38/00 ; A61K38/16 ; A61K39/00
Abstract:
The present invention relates generally to the novel use of incretin compounds (ICs) and amylinomimetic compounds to treat, prevent, or ameliorate a variety of metabolic conditions or diseases.
Public/Granted literature
- US20090312246A1 Uses of Glucoregulatory Proteins Public/Granted day:2009-12-17
Information query
IPC分类:
